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DOI 10.1186/s13024-016-0086-3ERRATUM Open AccessErratum to: Identification of novel CSF
biomarkers for neurodegeneration and
their validation by a high-throughput
multiplexed targeted proteomic assay
Wendy E. Heywood1,5, Daniela Galimberti2, Emily Bliss1, Ernestas Sirka1, Ross W. Paterson3, Nadia K. Magdalinou4,
Miryam Carecchio5, Emma Reid1, Amanda Heslegrave3, Chiara Fenoglio2, Elio Scarpini2, Jonathan M. Schott3,
Nick C. Fox3, John Hardy3, Kailash P. Bhatia3, Simon Heales1,6, Neil J. Sebire6, Henrik Zetterberg3,7 and Kevin Mills1,6*After publication of this work [1], we noted that the
names of two authors Kailash Bhatia and Henrik
Zetterberg had been misspelled. The names have now
been corrected above.
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